The E2A gene encodes transcription factors of the helixloop-helix (HLH) family which are implicated in cell-specific transcriptional control in several cell lineages, including pancreatic beta cells. In the present work, we show by deletion mapping of both the E2A protein itself and the Gal4-E2A fusion protein that the protein contains at least two distinct activation domains. One domain (located between amino acids 1 and 153) functions efficiently in a variety of mammalian cell lines. The second domain (located between amino acids 369 and 485) functions preferentially in pancreatic beta cell lines. The latter domain shows a pattern of heptad repeats of leucine residues characteristic of "leucine zipper" transcription factors; site-directed mutagenesis of leucines within this repeat led to substantial reductions in activity. The selective properties of this activation domain may contribute to cell-specific transcription directed by the E2A gene.
enhancers of immunoglobulin genes (9) (10) (11) (12) (13) . In vitro studies have shown that HLH proteins are capable of homo-and heterodimerization that is essential for DNA binding (14) . The muscle-specific HLH protein MyoD homodimerizes poorly yet heterodimerizes efficiently with E2A protein (14, 15) . These and other observations led to the notion that cell-specific transcription factors such as MEFi are composed of heterodimeric HLH complexes containing a cellspecific [or class B (14) ] HLH partner and a ubiquitous [class A (14) ] HLH partner, the E2A protein (7) . Such a pattern is also observed in pancreatic beta cells (6, 13, 16, 17) : the factor IEF1 appears to be a heterodimer of E2A protein with IESF1, a 25-kDa endocrine-specific protein (18) . By contrast, the lymphoid-specific E box binding factor BCF1/LEF1 appears to be a homodimeric complex of E2A proteins (6, 8, 19 ). The precise mechanism by which these complexes control cellspecific transcription is not completely understood: homoand heterodimeric HLH complexes containing E2A protein can bind efficiently in vitro to E boxes of genes expressed in
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It has previously been shown that the E2A proteins are able to activate transcription through multiple E box sequences in vivo (11, 12, 20) ; the activity was observed in both yeast and mammalian cells and was attributed to the N-terminal 2/3 of the protein, distinct from the HLH domain (11) . More recently, a transcriptional activation domain was localized to a 108-amino acid fragment of the human E2A protein with a putative loop-a-helical (LH) structure (21) . We now extend these observations. We have identified two separable activation domains, designated AD I and AD II, that show distinct characteristics: AD I is highly active in all cell types tested, whereas AD II, which overlaps the previously defined LH fragment (21), shows strong preferential activity in pancreatic beta cells.
MATERIALS AND METHODS
Plasmids. The E2A gene encodes two major gene products, the result ofalternative splicing events (9, 15) . The proteins are designated E47 and E12 (human) (9, 15, 22) , Al and A7 (mouse) (10), Panl and Pan2 (rat) (12), and shPanl and shPan2 (hamster) (13), respectively. An additional human cDNA (ITF-1) has been described which is identical to E47, except for a splice variation leading to a substitution ofthe N-terminal 100 amino acids of the encoded protein (11, 23) . Our mapping analysis was performed with the Al cDNA (10) . Using standard procedures (24), we introduced portions ofthe Al cDNA into the mammalian expression vector pRSV.HB, which contains the Rous sarcoma virus (RSV) promoter and simian virus 40 (SV40) virus splice and polyadenylylation signals (25, 26) . Expression of protein from these plasmids utilized the endogenous translation stop codons, except for construct TA1, for which a stop codon was present in the primer used for construction of the expression plasmid. The reporter plasmid used ] contained six copies of the IEB2 sequence upstream of the herpes simplex virus thymidine kinase (TK) promoter controlling the chloramphenicol acetyltransferase (CAT) (25) gene. IEB ("insulin enhancer box") is a key E box element found twice in the rat insulin I gene regulatory region (3, 27) . All Gal4 hybrid constructs were generated by polymerase chain reaction (PCR) using appropriate primers. All fragments were designed to contain an in-frame Bgl II site and were introduced into an expression vector encoding Gal4 DNA-binding domain (residues 1-147) (28) under the control of the RSV promoter (26). In addition, all bottom-strand primers include a stop codon to ensure translation termination at the correct location. SV40 splice sites and polyadenylylation signals were present at the 3' end Abbreviations: HLH, helix-loop-helix; LH, loop-a-helix; AD, activation domain; RSV, Rous sarcoma virus; TK, thymidine kinase; CAT, chloramphenicol acetyltransferase; EMSA, electrophoretic mobility shift analysis. *To whom reprint requests should be addressed. (6, 33) . EMSA was performed (6) (11, 12, 20) and pancreatic beta (HIT) (20) cells as previously reported (Fig. 1A , construct 1). N-terminal truncations showed a loss of trans-activation potential.
However, these proteins differed in their capacity to transactivate in distinct cells; for example, construct 2 (amino acids 369-652) showed reduced but still substantial transactivation capacity in HIT cells but virtually no activity in CHO cells (Fig. 1A) . Further deletions led to complete loss of activity in both cell types (Fig. 1A , constructs 3 and 4).
Since variations in the observed trans-activation capacity could result from alterations in stability, nuclear localization, or DNA-binding activity, we compared the accumulation of the truncated proteins by using EMSA with the E box probe IEB1 ( Fig. 1 devoid ofany trans-activation domain. For each value SEM is shown amino acids (Fig. 2A, constructs 1 and 2) . On the other hand, the region 369-485, while showing similar activity to the N-terminal domain in beta cells, showed little or no activity in CHO cells ( Fig. 2A, construct 3 ). Further removal of amino acids from N-or C-terminal portions led to substantial loss of activity (constructs 5, 7, 8, and 9 Within AD II is located a region of heptad repeats ofleucine residues (34, 35) with the sequence LX6LX6TX6LX6L. We performed site-directed mutagenesis to replace the first two leucine residues of the potential zipper (Leu-395 and Leu-402) with phenylalanine, a mutation that should substantially reduce the potential for protein-protein interaction (36). Indeed these mutations in the context of either the fragment 369-485 or the fragment 384-485 had substantial effects on the activity of AD II in HIT cells ( Fig. 2A , constructs 4 and 6).
Extracts of transfected cells were used to determine the binding activity of the expressed fusion protein, using a Gal4 DNA-binding site probe ( Fig. 2 B and C) . Extracts from transfected cells consistently showed doublet bands of binding activity, presumably reflecting alternative multimerization of the Gal4 fusion proteins by means of the Gal4-(1-147) region. Comparison of the intensity of the bands observed among the various constructs revealed only minor differences that cannot explain the differential activation potential of the constructs and thus indicates that the deletion analysis defines bona fide activation domains.
The striking functional differences between domains AD I and AD II in HIT compared with CHO cells ( Fig. 2A) prompted us to test their action in additional pancreatic beta cells as compared with other cell types. Using the mouse beta cell line ITC1 we observed, as with HIT cells, a strong action of AD 11 (4.7-fold higher than AD I) (Fig. 3) . On the other hand, five additional non-beta cells-BHK, Ltk-, SK-Hepl, HepG2, and HeLa-showed a much lower activity of AD II, 0.01-0.22 of that observed with AD I (Fig. 3) . Thus duce widely diverse effects on transcription; mutations of homeobox genes, for example, lead to distinct and characteristic phenotypes in Drosophila, yet the encoded proteins show relatively low DNA-binding specificity in vitro (reviewed in ref. 40 ). Therefore, additional specificity must be generated through functional domains distinct from the DNA-binding capacity of the protein (41-43).
The HLH proteins contribute toward diverse developmental programs in Drosophila (44) and in higher eukaryotes (45); distinct mammalian cell lineages appear to contain characteristic heterodimeric complexes consisting of a lineagerestricted HLH protein together with a widely distributed HLH protein, the E2A protein. The precise role of the E2A protein is not established; conceivably its major function could be to permit efficient DNA binding of the cell-specific HLH protein-typically such proteins bind weakly to E boxes as homodimers; alternatively, the E2A protein could participate actively by providing activation domains with either ubiquitous or lineage-restricted potential. For example, it has been shown that an E2A protein containing a portion of the basic-HLH region of MyoD is able to activate the myogenic program, albeit at reduced efficiency (46) . To further examine these issues we have analyzed the transcription activation domains of the E2A protein.
We have identified and mapped two distinct transcription activation domains in the E2A protein, designated AD I and AD II. Neither domain shows close similarity to previously reported activation domains of other genes. AD I has a high concentration of serine (34/153) and glycine (19/153) residues (Fig. 4A) . Interestingly, one ofthe human E2A proteins, ITF-1, differs extensively from E12/E47 and mouse E2A in the first 100 amino acids at the N terminus (Fig. 4) (11, 23) . This region of ITF-1 shows little or no trans-activation capacity (21). AD II has a high concentration of serine (17/117) and leucine (18/117) residues (Fig. 4B) . In addition, AD II contains a heptad repeat of leucine residues (Fig. 4B ) characteristic of "leucine zipper" proteins such as C/EBP, Jun, and Fos; the repeat is involved in generating the coiledcoil dimer structure required for function of this class of proteins (47). A heptad repeat of leucines has also been identified in a class ofHLH proteins designated HLH-zip and including the proteins myc (48), USF (49), and TFE3 (50). In the HLH-zip subfamily, the zipper region is located adjacent to the HLH and has been shown to play a role in stabilizing HLH-mediated dimerization and to restrict the dimerization specificity of these proteins (51, 52) . By contrast, in the E2A proteins, the heptad repeat is separated from the HLH region by over 100 amino acids and has not yet been assigned a clear functional role in the molecule; it is clearly not essential for E box DNA binding (9) . Both in the HLH-zip subfamily and in other zipper transcription factors, the transcription activation domain maps to regions ofthe protein distinct from the zipper (50). In our experiments, site-directed mutation of the first two leucine residues in the repeat of AD II led to substantial reduction in trans-activation potential, suggesting an important role in directing transcription activation, perhaps involving interaction with other zipper proteins. However, additional complexity is probably involved, since the a-helix-destabilizing amino acids proline and glycine are present between the last two leucines of the repeat, making it unlikely that an a-helical structure could form at the C terminus of the leucine repeat. Furthermore, in our experiments, the leucine repeat region alone is not an efficient trans-activator: downstream sequences are required in addition. Interactions between HLH proteins and leucine zipper proteins have previously been suggested-for example, the functional antagonism between the c-Jun protein and myogenesis may involve an interaction between the zipper region of the c-Jun protein (53); however the biochemical target appears to be not the E2A protein but rather the HLH region of MyoD (53) and myogenin (54) .
The activation domain identified by our studies as AD II overlaps extensively (Fig. 4) 
